CORRIGENDUM by Sethi, Sujata & Bhargava, S.C.
LETTERS TO EDITOR 
some pharmaceutical companies are organising 
"updates" for trainees in each zone. These 
workshops could be conducted by the many skilled 
researchers in the country, and would aim not only 
to teach research methods but also to strengthen 
inter-department research collaborative networks, 
teach how to write research proposals and to 
access funds from the growing number of donor 
agencies. Let us be hopeful that psychiatric 
research in India can capitalise on the 
considerable strengths it already has. The solution 
appear relatively straightforward. Does our Society 
have the will? 
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CORRIGENDUM 
In the article entitled, "Rabbit Syndrome- An acute 
complication of Neuroleptic Medication" , 
published in the July, 2001 issue of Indian Journal 
of Psychiatry ,the name of S.C.Bhargava co-author 
was left out inadvertently. The authors are Sujata 
Sethi & S.C.Bhargava. 
SUJATA SETHI', MD, Lecturer & S.C. BHARGAVA MD. 
Associate Professor,Department of Psychiatry, PtB.D. 
Sharma Postgraduate Institute of Medical Sciences, 
Rohtak-124001 Haryana(lndia) ('122/8, Shivaji Colony, 
Rohtak-124001 
Editor 
NOTES & NEWS 
NEW RESEARCH FUNDS AVAILABLE FOR 
TREATMENT TRIALS FOR SCHIZOPHRENIA 
AND BIPOLAR DISORDER 
The Stanley Foundation announces the 
availability of $10-$15 million per year in new 
funds specifically designated to support clinical 
trials for schizophrenia or bipolar disorder The 
Foundation will support studies on compounds in 
development, studies on the off-label use of 
existing compounds, and studies of novel and 
indigenous compounds that may be of benifit for 
these disorders. A variety of study designs will 
be considered, including adjunctive trials, 
uncontrolled pilot trials, and randomized controlled 
trials. Trials may be from single site or from multiple 
collaborating sites. A complete list of drug trials 
currently being supported by the Foundation is 
available at www Stanley research org. 
Funding for the trials may range from 
$50,000 up to $ 300,000 per year for up to three 
years depending on the design Indirect costs can 
be paid up to 15 percent as part of the total grant 
Submissions will be reviewed by a scientific 
advisory board Application can be submitted on-
line at www.stanleyresearch.org. Questions should 
be directed to Drs David Daniel, Michael Knable 
or Fuller Torrey at wilsonk @ Stanley research.org. 
Deadlines for submission of application: 
March 1 & October 1 of each year 
Stanley Foundation Research Programs 
5430 Grosvenor Lane,Suite 200,Bethesda, 
Maryland USA. 
Telephone:(301)571-0760 Fax: (301)571-0769 
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